QYUNS-B (02509) Rises Over 3% Again as Bispecific Antibody Pipeline Advances Overseas into Clinical Phase

Stock News12-11

QYUNS-B (02509) gained over 3% again, rising 3.26% to HK$20.9 by the time of writing, with a trading volume of HK$3.06 million. The company announced that on December 8, it received a US$5 million milestone payment from its partner Caldera Therapeutics, Inc. This payment was triggered after QX030N/CLD-423, a bispecific antibody developed by QYUNS-B, obtained ethical approval for Phase I clinical trials from the Human Research Ethics Committee (HREC) in Australia.

The company plans to initiate clinical trials for QX030N/CLD-423 in early 2026. This approval marks the official entry of QYUNS-B's bispecific antibody pipeline into the clinical stage overseas, further strengthening its leading position in autoimmune and allergic disease treatments. Both QYUNS-B and Caldera will accelerate project development to achieve more clinical progress soon.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186184034?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186184034","market":"sh","top_or_hot":-1,"title":"QYUNS-B (02509) Rises Over 3% Again as Bispecific Antibody Pipeline Advances Overseas into Clinical Phase","media":"Stock News","content":"<p>QYUNS-B (02509) gained over 3% again, rising 3.26% to HK$20.9 by the time of writing, with a trading volume of HK$3.06 million. The company announced that on December 8, it received a US$5 million milestone payment from its partner Caldera Therapeutics, Inc. This payment was triggered after QX030N/CLD-423, a bispecific antibody developed by QYUNS-B, obtained ethical approval for Phase I clinical trials from the Human Research Ethics Committee (HREC) in Australia.</p>\n<p>The company plans to initiate clinical trials for QX030N/CLD-423 in early 2026. This approval marks the official entry of QYUNS-B's bispecific antibody pipeline into the clinical stage overseas, further strengthening its leading position in autoimmune and allergic disease treatments. Both QYUNS-B and Caldera will accelerate project development to achieve more clinical progress soon.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B (02509) Rises Over 3% Again as Bispecific Antibody Pipeline Advances Overseas into Clinical Phase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B (02509) Rises Over 3% Again as Bispecific Antibody Pipeline Advances Overseas into Clinical Phase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-11 15:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) gained over 3% again, rising 3.26% to HK$20.9 by the time of writing, with a trading volume of HK$3.06 million. The company announced that on December 8, it received a US$5 million milestone payment from its partner Caldera Therapeutics, Inc. This payment was triggered after QX030N/CLD-423, a bispecific antibody developed by QYUNS-B, obtained ethical approval for Phase I clinical trials from the Human Research Ethics Committee (HREC) in Australia.</p>\n<p>The company plans to initiate clinical trials for QX030N/CLD-423 in early 2026. This approval marks the official entry of QYUNS-B's bispecific antibody pipeline into the clinical stage overseas, further strengthening its leading position in autoimmune and allergic disease treatments. Both QYUNS-B and Caldera will accelerate project development to achieve more clinical progress soon.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1186184034","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186184034","pubTimestamp":1765438478,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) gained over 3% again, rising 3.26% to HK$20.9 by the time of writing, with a trading volume of HK$3.06 million. The company announced that on December 8, it received a US$5 million...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02509":"荃信生物-B"},"translate_title":"双特异性抗体管线海外挺进临床期QYUNS-B(02509)再涨超3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) gained over 3% again, rising 3.26% to HK$20.9 by the time of writing, with a trading volume of HK$3.06 million. The company announced that on December 8, it received a US$5 million milestone payment from its partner Caldera Therapeutics, Inc. This payment was triggered after QX030N/CLD-423, a bispecific antibody developed by QYUNS-B, obtained ethical approval for Phase I clinical trials from the Human Research Ethics Committee (HREC) in Australia.\nThe company plans to initiate clinical trials for QX030N/CLD-423 in early 2026. This approval marks the official entry of QYUNS-B's bispecific antibody pipeline into the clinical stage overseas, further strengthening its leading position in autoimmune and allergic disease treatments. Both QYUNS-B and Caldera will accelerate project development to achieve more clinical progress soon.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186184034","isCrawlerRequest":true}